Articles

Cabazitaxel (Jevtana) is approved as third-line therapy for patients with metastatic castration-resistant prostate cancer (CRPC) after treatment with docetaxel and an androgen receptor inhibitor. Read More ›

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between April 13, 2021, and May 21, 2021. Read More ›

Use of chemotherapy near the end of life in patients with metastatic breast cancer may potentially negatively impact quality of life. Read More ›

Low-dose tamoxifen could be used for prevention and to increase sensitivity of mammograms in premenopausal women. Read More ›

Researchers report on early results from an effort to develop a predictive model and targeted strategies for communication and intervention for cancer screening during the COVID-19 pandemic. Read More ›

Based on current drug pricing strategies in the United States, ribociclib combination therapy is unlikely to be cost-effective for treating postmenopausal patients with HR-positive HER2-negative advanced breast cancer. Read More ›

Read More ›